Gene Therapies

Regenerative Patch Technologies advances its stem cell therapy for dry AMD, signaling a potential shift from merely slowing blindness to actively improving vision.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

Eli Lilly's takeover of Adverum signals a major push into ocular gene therapy. Can a one-time injection for vision loss disrupt a multi-billion dollar market?

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.